---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-246171"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:23:32.783377+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics: Phase 2 LD IL-2 in Alzheimer's meets endpoints, shows cognitive stabilization

## Summary
- Study met primary safety endpoint and secondary endpoint for Treg expansion with no off-target effects.
- LD IL-2 q4wks showed cognitive stabilization (ADAS-Cog14 4.93-point improvement vs placebo, p=0.061).
- Significant improvement in CSF Aß42 (p=0.045) and trend toward stabilizing CSF NfL (p=0.060) with q4wks.
- Company likely advancing LD IL-2 q4wks; supports COYA 302 combination in ALS and FTD.
- No serious adverse events or deaths; common AEs were mild injection-site erythema and eosinophil increases.

## SEC filing metadata
- accession: 0001193125-24-246171
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524246171/0001193125-24-246171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524246171/d821192d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-246171
- JSON: https://secwatch.observer/filing/0001193125-24-246171.json
- Plain text: https://secwatch.observer/filing/0001193125-24-246171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.